KLK3 and prostate carcinoma: The success of definitive external beam radiotherapy (EBRT) for prostate cancer is often measured via control of prostate-specific antigen (PSA) levels.1,2 This occurs largely because PSA tests are inexpensive and widely available and provide an early indicator of treatment response.